Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Indole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.94 |
| ▸ | CA1 | P00915 | 2/20 | 0.94 |
| ▸ | CA4 | P22748 | 2/20 | 0.94 |
| ▸ | CA6 | P23280 | 2/20 | 0.94 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.94 |
| ▸ | CA2 | P00918 | 1/20 | 0.94 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.94 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.94 |
| ▸ | ITGAL | P20701 | 1/20 | 0.94 |
| ▸ | ADK | P55263 | 1/20 | 0.94 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole SCHEMBL7004015 | 1.00 | AHR (0.94) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL27362939 | 1.00 | AHR (0.94) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL29559913 | 1.00 | AHR (0.94) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL28260194 | 0.97 | AHR (0.90) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL775354 | 0.97 | AHR (0.90) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL29352896 | 0.97 | — | — | |
| Indole SCHEMBL30463845 | 0.97 | — | — | |
| Indole SCHEMBL1160186 | 0.97 | AHR (1.00) | AHRCA1CA4CA6TRPA1 | |
| Indole SCHEMBL30250492 | 0.97 | — | — | |
| Indole SCHEMBL698 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113980049-A | Preparation method of diphenylphosphine substituted indole derivative | 河南省科学院化学研究所有限公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2019169621-A1 | MEDICATION CARRIER AND SYSTEM FOR COMBINED MEDICATIONS | 润生药业有限公司 | 2019-09-12 | — | — | WO | claimed |
| CN-108976242-A | Synthesis a kind of while that there is photochromic and ion detection function Indoline spiropyran derivative | 南京大学 | 2018-12-11 | — | — | CN | claimed |
| CN-106414376-A | Process for obtaining optically active pirlindole enantiomers and salts thereof | 特克尼梅德医疗技术股份公司 | 2017-02-15 | — | — | CN | claimed |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-RE50455-E1 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-20 | — | — | US | disclosed |
| CN-115867346-B | Kinase inhibitors | GB005股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | AMERICAN HOME PRODUCTS CORPORATION | 2003-08-14 | — | — | US | disclosed |
| WO-2003018555-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) | 2003-03-06 | — | — | WO | disclosed |
| CN-1299347-A | Inhibitor of phospholipase enzymes | GENETICS INST (US) | 2001-06-13 | — | — | CN | disclosed |
| EP-1056719-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043651-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1982000143-A1 | HETEROCYCLIC COMPOUNDS,METHOD FOR PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ AG (CH) | 1982-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | AHR 472/4885CA1 4207/4885CA4 4101/4885 |
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | PLA2G4C, PLA2G4B, PLA2G4A | AHR 4427/4885CA1 1996/4885CA4 2960/4885 |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | AHR 472/4885CA1 4207/4885CA4 4101/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | AHR 561/4885CA1 2625/4885CA4 2303/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | AHR 1328/4885CA1 3656/4885CA4 2372/4885 |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | AHR 472/4885CA1 4207/4885CA4 4101/4885 |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | AHR 1088/4885CA1 4580/4885CA4 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.